Often patients reach their goal weight and feel good about themselves. Then, because of the initial success, they decide the ...

Aside from the disappointing headline number, investors and analysts focused on another puzzling data point: only 57% of patients in the trial were on the highest dose-strength of the medicine at ...

Regarding the CagriSema trial, only 57% of participants reached the highest dose of the drug during the ... from strong GLP-1 demand and a valuation rebound from depressed sentiment, making ...

ITV viewers slammed the show for 'sending a dangerous message' and 'medical misinformation' after a guest, showcased her before and after pictures.

The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.

MCD began to rebound at midyear and delivered better-than ... While MariTide is being compared to the likes of Ozempic and ...

aquaArts studio/Getty A new viral drink claims to replicate the effects of the weight-loss medication Mounjaro — with just four ingredients. Calling it “Natural Mounjaro,” fans claim that ...

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from the federal drug shortage list ...

Mounjaro is a GLP-1 inhibitor developed to help people with diabetes regulate their blood glucose. Elon Musk, the 53-year-old CEO of Tesla and SpaceX, recently shared a festive image of himself ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...